AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11835692 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint tele-consultation
Number of subjects: 2094
Study 11835692 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient appointment
Number of subjects: 2094
Study 11327625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg)
Number of subjects: 60
Study 11327625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic subjects (HbA1c ≥ 6.0%)
Number of subjects: 60
Study 11327625 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 60
Study 9040452 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (0.1 mg) plus thiazide clopamid (5 mg)
Number of subjects: 273
Study 9040452 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (0.1 mg)
Number of subjects: 273
Study 9040452 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide clopamid (5 mg)
Number of subjects: 273
Study 9040452 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 mg)
Number of subjects: 273
Study 9040452 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 273
Study 8174419 — intervention group
Group type: EXPERIMENTAL
Intervention: fedotozine 30 mg three times a day
Number of subjects: 146
Study 8174419 — intervention group
Group type: EXPERIMENTAL
Intervention: fedotozine 30 mg and 70 mg
Number of subjects: 146
Study 8174419 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study 8174419 — intervention group
Group type: EXPERIMENTAL
Intervention: fedotozine (all doses)
Number of subjects: 146
Study 3217992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (P) 60 mg/m2/day on days 1 and 2 every 28 days
Number of subjects: 44
Study 3217992 — intervention group
Group type: COMPARATOR
Intervention: CAP (cyclophosphamide 750 mg/m2, adriamycin 50 mg/m2, cisplatin 50 mg/m2 on day 1 every 21 days)
Number of subjects: 44
Study 3217992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (P)
Number of subjects: 44
Study 3217992 — intervention group
Group type: COMPARATOR
Intervention: CAP
Number of subjects: 44
Study 1567662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 265
Study 900585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol metered-dose inhaler
Number of subjects: 30
Study 900585 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol metered-dose inhaler
Number of subjects: 30
Study 30926293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vibratory stimulation (100-Hz vibration applied to the popliteal fossa for 3 to 5 seconds prior to and during TPI)
Number of subjects: 60
Study 30926293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration applied)
Number of subjects: 60
Study 30926293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vibratory stimulation
Number of subjects: 60
Study 30926293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30081451 — intervention group
Group type: EXPERIMENTAL
Intervention: six-month lunch provision
Number of subjects: 223
Study 26062925 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-CT
Number of subjects: 138
Study 26062925 — intervention group
Group type: COMPARATOR
Intervention: EDUC
Number of subjects: 138
Study 23629815 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional expression
Number of subjects: 142
Study 23629815 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional expression
Number of subjects: 142
Study 23629815 — intervention group
Group type: EXPERIMENTAL
Intervention: Wandering behavior
Number of subjects: 142
Study 23629815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive status
Number of subjects: 142
Study 23629815 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, education, gender, facility type, mobility, time of day
Number of subjects: 142
Study 21814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active red LLLT (660 nm, 50 mW, 17.85 W/cm², 100 s irradiation per point, 5 J, total 20 J irradiated per muscle)
Number of subjects: 10
Study 21814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infrared LLLT (830 nm, 50 mW, 17.85 W/cm², 100 s irradiation per point, 5 J, total 20 J irradiated per muscle)
Number of subjects: 10
Study 21814736 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 10
Study 21814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active red LLLT (660 nm)
Number of subjects: 10
Study 21814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infrared LLLT (830 nm)
Number of subjects: 10
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Antispasmodics
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT4 agonists
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-diarrheal agents
Number of subjects: 0
Study 19829284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Number of subjects: 0
Study 17992639 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin
Number of subjects: 55
Study 17992639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 15919319 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.5% (0.1 mL/kg(‐1)/h(‐1)) in thoracic paravertebral block (TPVB) group
Number of subjects: 40
Study 15919319 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia with ketoprofen, paracetamol, and PCA with intravenous morphine (control group)
Number of subjects: 40
Study 11991693 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous polyamide sutures (Ethilon)
Number of subjects: 170
Study 11991693 — intervention group
Group type: COMPARATOR
Intervention: Metallic skin staples
Number of subjects: 170
Study 10086938 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for three years
Number of subjects: 15
Study 10086938 — intervention group
Group type: COMPARATOR
Intervention: Control group (Down's syndrome children not receiving GH)
Number of subjects: 15
Study 10086938 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 15
Study 7551664 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection without washout
Number of subjects: 60
Study 7551664 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint washout with normal saline
Number of subjects: 60
Study 7551664 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint washout with normal saline and steroid injection
Number of subjects: 60
Study 7551664 — intervention group
Group type: COMPARATOR
Intervention: Joint washout alone
Number of subjects: 60
Study 2189077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 44
Study 2189077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (increased dosage from 10 to 20 mg daily in 12 patients)
Number of subjects: 44
Study 2189077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (with additional antihypertensive agents in 8 patients)
Number of subjects: 44
Study 379093 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% sodium fluoride paste
Number of subjects: 0
Study 379093 — intervention group
Group type: COMPARATOR
Intervention: Sham burnishing with placebo paste
Number of subjects: 0
Study 379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulus method
Number of subjects: 0
Study 379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air stimulus method
Number of subjects: 0
Study 31009419 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine plaster (LP5)
Number of subjects: 36
Study 31009419 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 36
Study 28378156 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 0
Study 28378156 — intervention group
Group type: COMPARATOR
Intervention: Traditional debridement (Control)
Number of subjects: 0
Study 26451863 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF in segment L IV/V (group 1)
Number of subjects: 60
Study 26451863 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF in segment L V/S I (group 2)
Number of subjects: 60
Study 26451863 — intervention group
Group type: COMPARATOR
Intervention: TLIF in both segments
Number of subjects: 60
Study 23593620 — intervention group
Group type: COMPARATOR
Intervention: ABBM alone
Number of subjects: 24
Study 23593620 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBM + rhPDGF
Number of subjects: 24
Study 21233500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual closed-loop administration of propofol and remifentanil
Number of subjects: 196
Study 21233500 — intervention group
Group type: COMPARATOR
Intervention: Manual administration of propofol and remifentanil
Number of subjects: 196
Study 19407307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated standard anatomical stem
Number of subjects: 12
Study 19407307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated customised stem
Number of subjects: 12
Study 17324764 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial ligation at three different levels
Number of subjects: 84
Study 17324764 — intervention group
Group type: COMPARATOR
Intervention: Partial exeresis of the short saphenous vein
Number of subjects: 84
Study 15608388 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawasaki disease
Number of subjects: 56
Study 15608388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute febrile illnesses
Number of subjects: 56
Study 15608388 — intervention group
Group type: COMPARATOR
Intervention: Henoch-Schönlein purpura
Number of subjects: 56
Study 12390612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL of normal saline, 0.9% intravenously)
Number of subjects: 0
Study 9795856 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Number of subjects: 40
Study 9795856 — intervention group
Group type: COMPARATOR
Intervention: Amethocaine
Number of subjects: 40
Study 7541859 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuprolide acetate depot and flutamide) for 3 months before radical prostatectomy
Number of subjects: 287
Study 7541859 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (radical prostatectomy without preoperative androgen deprivation)
Number of subjects: 287
Study 2565117 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 8
Study 2565117 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 8
Study 2565117 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.1%
Number of subjects: 8
Study 2565117 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 8
Study 769156 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (Histamine H2-receptor antagonist)
Number of subjects: 31
Study 769156 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide
Number of subjects: 31
Study 769156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30968986 — intervention group
Group type: EXPERIMENTAL
Intervention: ParActin® 300 mg/day
Number of subjects: 103
Study 30968986 — intervention group
Group type: EXPERIMENTAL
Intervention: ParActin® 600 mg/day
Number of subjects: 103
Study 30968986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 28856913 — intervention group
Group type: EXPERIMENTAL
Intervention: Real external transcutaneous nerve stimulation (60 Hz, 16 mA, 20 minutes)
Number of subjects: 38
Study 28856913 — intervention group
Group type: COMPARATOR
Intervention: Sham external transcutaneous nerve stimulation (2 mA)
Number of subjects: 38
Study 27047398 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditative movement exercises (MM) over a 16-week period
Number of subjects: 20
Study 27047398 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 20
Study 24799326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days
Number of subjects: 1118
Study 24799326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 375 mg every 6 hours for 10 days
Number of subjects: 1118
Study 24799326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 125 mg every 6 hours for 10 days
Number of subjects: 1118
Study 24799326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole in patients with severe CDI
Number of subjects: 1118
Study 22354306 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 71
Study 22354306 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (CLI)
Number of subjects: 71
Study 21365840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL triamcinolone acetonide plus 0.5 mL saline (experimental group, n = 46)
Number of subjects: 90
Study 21365840 — intervention group
Group type: COMPARATOR
Intervention: 1 mL saline solution (control group, n = 44)
Number of subjects: 90
Study 17562269 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)
Number of subjects: 32
Study 17562269 — intervention group
Group type: COMPARATOR
Intervention: Minimal Incision Thoracotomy (MIT)
Number of subjects: 32
Study 15808038 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prednisone orally for 1 or 2 days
Number of subjects: 0
Study 15808038 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo treatment
Number of subjects: 0
Study 11973198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 33
Study 11973198 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 33
Study 11973198 — intervention group
Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 33
Study 9616530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education (77 patients, visits every third month)
Number of subjects: 162
Study 9616530 — intervention group
Group type: COMPARATOR
Intervention: Conventional education (80 patients, advice at baseline only)
Number of subjects: 162
Study 9616530 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 162
Study 8585698 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet (740 mg phytosterols/day)
Number of subjects: 12
Study 8585698 — intervention group
Group type: COMPARATOR
Intervention: Control diet (29 mg phytosterols/day)
Number of subjects: 12
Study 8585698 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet
Number of subjects: 12
Study 2705405 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 67
Study 2705405 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 67
Study 411165 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG 2% nasal solution
Number of subjects: 32
Study 411165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31382717 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm digital metrology adjustment during percutaneous vertebroplasty
Number of subjects: 94
Study 31382717 — intervention group
Group type: COMPARATOR
Intervention: C-arm adjustment based on experience (Control group)
Number of subjects: 94
Study 28218554 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical techniques
Number of subjects: 0
Study 26446505 — intervention group
Group type: COMPARATOR
Intervention: Chincup therapy
Number of subjects: 67
Study 26446505 — intervention group
Group type: COMPARATOR
Intervention: Facemask therapy (combined with rapid palatal expansion)
Number of subjects: 67
Study 23650877 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual training
Number of subjects: 0
Study 23650877 — intervention group
Group type: COMPARATOR
Intervention: Conceptual training
Number of subjects: 0
Study 21683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 905
Study 21683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) program
Number of subjects: 905
Study 21683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LST + Strengthening Families Program: For Parents and Youth 10-14 (SFP10-14)
Number of subjects: 905
Study 18079261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program (non-macronutrient-specific energy restriction for 15 weeks)
Number of subjects: 10
Study 18079261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 10
Study 17043337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg 3 times daily for 10 days (n = 43)
Number of subjects: 87
Study 17043337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 87
Study 12698083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol, 800 mg per day for 12 months
Number of subjects: 30
Study 12698083 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 30
Study 12698083 — intervention group
Group type: COMPARATOR
Intervention: Ursodiol and Placebo
Number of subjects: 30
Study 10730733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 50
Study 10730733 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia
Number of subjects: 50
Study 8959531 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin or minocycline (oral medication) and/or nadifloxacin cream or clindamycin hydrochloride lotion (topical medication) for 1‐8 weeks
Number of subjects: 7
Study 8959531 — intervention group
Group type: EXPERIMENTAL
Intervention: nadifloxacin, ofloxacin, erythromycin, clindamycin hydrochloride, tetracycline hydrochloride, minocycline, doxycycline, ampicillin, cephalexin and gentamycin (susceptibility testing)
Number of subjects: 7
Study 8195352 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 98,734 (12.5, 25, 50 or 100 mg twice daily for 4 days)
Number of subjects: 96
Study 3308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (linoleic acid)
Number of subjects: 21
Study 3308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Number of subjects: 21
Study 3308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream (saturated fat)
Number of subjects: 21
Study 29694685 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly (QM)
Number of subjects: 364
Study 29694685 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab followed by Denosumab 60 mg every 6 months (Q6M)
Number of subjects: 364
Study 29694685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 29694685 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg QM
Number of subjects: 364
Study 29694685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to Denosumab
Number of subjects: 364
Study 29694685 — intervention group
Group type: COMPARATOR
Intervention: Transition to Placebo
Number of subjects: 364
Study 29694685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 364
Study 24989147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 118) - regularly exercising with a new sports companion for eight weeks
Number of subjects: 220
Study 24989147 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 220
Study 22922235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused day-treatment group program (2 days with three nonverbal and two group psychotherapy sessions per week)
Number of subjects: 72
Study 22922235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused day-treatment group program (same amount of sessions spread over 3 days per week)
Number of subjects: 72
Study 22922235 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 72
Study 20473051 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TCPRFT
Number of subjects: 50
Study 20473051 — intervention group
Group type: COMPARATOR
Intervention: Sham TCPRFT
Number of subjects: 50
Study 18723251 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC chart feedback
Number of subjects: 75
Study 18723251 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC chart feedback in conjunction with structured diagnostic tools
Number of subjects: 75
Study 18723251 — intervention group
Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 75
Study 15885789 — intervention group
Group type: COMPARATOR
Intervention: Focal laser photocoagulation (MP)
Number of subjects: 60
Study 15885789 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal laser photocoagulation combined with posterior sub-Tenon's capsule triamcinolone injection (FL + PSTI)
Number of subjects: 60
Study 12655794 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 25
Study 12655794 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus GM-CSF
Number of subjects: 25
Study 10553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback assisted relaxation
Number of subjects: 18
Study 10553485 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 18
Study 7671437 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine i.v. infusion (0.07 mmol/kg per min)
Number of subjects: 5
Study 7671437 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 5
Study 2151628 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg, Hemovasal 100 b.i.d.)
Number of subjects: 40
Study 6776858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen (O2) therapy
Number of subjects: 203
Study 6776858 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal O2 therapy
Number of subjects: 203